1. Home
  2. RCI vs INCY Comparison

RCI vs INCY Comparison

Compare RCI & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rogers Communication Inc.

RCI

Rogers Communication Inc.

HOLD

Current Price

$36.51

Market Cap

17.7B

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$100.44

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCI
INCY
Founded
1960
1991
Country
Canada
United States
Employees
24000
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Commercial Physical & Biological Resarch
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.7B
17.0B
IPO Year
N/A
1994

Fundamental Metrics

Financial Performance
Metric
RCI
INCY
Price
$36.51
$100.44
Analyst Decision
Hold
Buy
Analyst Count
3
21
Target Price
$44.00
$103.52
AVG Volume (30 Days)
1.1M
1.3M
Earning Date
04-22-2026
04-28-2026
Dividend Yield
4.01%
N/A
EPS Growth
N/A
4173.33
EPS
N/A
1.47
Revenue
N/A
$3,394,635,000.00
Revenue This Year
$6.78
$10.44
Revenue Next Year
$1.45
$10.99
P/E Ratio
$4.12
$67.09
Revenue Growth
N/A
13.67
52 Week Low
$24.80
$62.84
52 Week High
$41.14
$112.29

Technical Indicators

Market Signals
Indicator
RCI
INCY
Relative Strength Index (RSI) 53.05 59.56
Support Level $35.74 $99.10
Resistance Level $38.86 $102.07
Average True Range (ATR) 0.96 3.17
MACD 0.22 0.32
Stochastic Oscillator 54.35 74.84

Price Performance

Historical Comparison
RCI
INCY

About RCI Rogers Communication Inc.

Rogers Communications is the largest wireless service provider in Canada with more than 11 million subscribers, equating to one-third of the total Canadian market. Rogers' wireless business accounts for more than half of total revenue and has been growing at a higher rate than other segments. The cable segment, which provides about 38% of total revenue after acquiring Shaw, offers home internet, television, and landline phone service to consumers and businesses. Remaining sales come from Rogers' media unit, which owns and operates various television and radio stations and major Toronto sports franchises, including the Blue Jays, Maple Leafs, Raptors, Toronto FC, and Argonauts.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: